Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $32,375.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 2,500 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $12.95, for a total value of $32,375.00. Following the sale, the chief financial officer owned 119,010 shares in the company, valued at approximately $1,541,179.50. The trade was a 2.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kory James Wentworth also recently made the following trade(s):

• On Tuesday, March 10th, Kory James Wentworth sold 11,388 shares of Entrada Therapeutics stock. The stock was sold at an average price of $13.02, for a total value of $148,271.76.
• On Monday, March 9th, Kory James Wentworth sold 5,089 shares of Entrada Therapeutics stock. The shares were sold at an average price of $13.00, for a total value of $66,157.00.
• On Wednesday, March 4th, Kory James Wentworth sold 7,988 shares of Entrada Therapeutics stock. The shares were sold at an average price of $12.25, for a total value of $97,853.00.

Entrada Therapeutics Stock Performance

TRDA opened at $13.15 on Friday. The company has a market cap of $503.38 million, a price-to-earnings ratio of -3.80 and a beta of -0.15. Entrada Therapeutics, Inc. has a 1-year low of $4.93 and a 1-year high of $13.66. The company’s fifty day moving average price is $11.80 and its two-hundred day moving average price is $9.69.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.38. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. The business had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $7.41 million. As a group, equities analysts forecast that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on TRDA shares. Oppenheimer started coverage on Entrada Therapeutics in a research note on Wednesday, January 28th. They set an “outperform” rating and a $21.00 target price on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Friday, March 27th. Wall Street Zen cut Entrada Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Guggenheim upgraded Entrada Therapeutics to a “strong-buy” rating in a report on Wednesday, February 11th. Finally, Cantor Fitzgerald started coverage on Entrada Therapeutics in a research report on Wednesday. They set an “overweight” rating for the company. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.50.

Hedge Funds Weigh In On Entrada Therapeutics

Several large investors have recently modified their holdings of TRDA. Millennium Management LLC grew its position in Entrada Therapeutics by 391.2% during the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after purchasing an additional 666,287 shares during the last quarter. Citadel Advisors LLC increased its position in shares of Entrada Therapeutics by 234.5% during the third quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock valued at $1,947,000 after acquiring an additional 235,384 shares in the last quarter. Baker BROS. Advisors LP lifted its position in Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after acquiring an additional 206,911 shares in the last quarter. Qube Research & Technologies Ltd boosted its stake in Entrada Therapeutics by 115.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company’s stock valued at $1,670,000 after purchasing an additional 154,143 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Entrada Therapeutics by 4,767.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 148,212 shares of the company’s stock valued at $860,000 after purchasing an additional 145,167 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.